TY - JOUR
AU - Jacobs, Angus
AU - Morley, Steven
AU - Samuel, Kay
AU - Morgan, Katie
AU - Boswell, Lyndsey
AU - Kendall, Timothy J.
AU - Dorward, David A.
AU - Fallowfield, Jonathan A
AU - Hayes, Peter Clive
AU - Plevris, John
PY - 2024
DA - August
TI - Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19
JO - World Journal of Gastroenterology
EP - 3716
VL - 30
IS - 31
DO - http://dx.doi.org/10.3748/wjg.v30.i31.3705
AB - Metabolic dysfunction-associated steatotic liver disease (MASLD), characterised by hepatic lipid accumulation, causes inflammation and oxidative stress accompanied by cell damage and fibrosis. Liver injury (LI) is also frequently reported in patients hospitalised with coronavirus disease 2019 (COVID-19), while pre-existing MASLD increases the risk of LI and the development of COVID-19-associated cholangiopathy. Mechanisms of injury at the cellular level remain unclear, but it may be significant that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19, uses angiotensin-converting expression enzyme 2 (ACE2), a key regulator of the ‘anti-inflammatory’ arm of the renin-angiotensin system, for viral attachment and host cell invasion.
PB - Baishideng Publishing Group
UR - https://www.research.ed.ac.uk/en/publications/d7e00a40-86f1-4369-8c03-f5d7d794eb27
KW - Coronavirus (COVID-19)
ER